| Literature DB >> 17147826 |
Robert J Hancox1, Richie Poulton, D Robin Taylor, Justina M Greene, Christene R McLachlan, Jan O Cowan, Erin M Flannery, G Peter Herbison, Malcolm R Sears, Nicholas J Talley.
Abstract
BACKGROUND: Several studies have reported an association between asthma and gastro-oesophageal reflux, but it is unclear which condition develops first. The role of obesity in mediating this association is also unclear. We explored the associations between respiratory symptoms, lung function, and gastro-oesophageal reflux symptoms in a birth cohort of approximately 1000 individuals.Entities:
Mesh:
Year: 2006 PMID: 17147826 PMCID: PMC1702357 DOI: 10.1186/1465-9921-7-142
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Prevalence of respiratory outcomes in those with and without reflux symptoms and irritable bowel syndrome at age 26 years
| % prevalence | % with respiratory condition | Mean FEV1/FVC | ||||
| Asthma | Wheeze | Cough | BDR | |||
| No Reflux symptoms* | 85.8 | 17.2 | 35.0 | 12.4 | 6.9 | 81.7 % |
| Heartburn | 12.5 | 28.3 | 48.7 | 23.9 | 14.2 | 80.9 % |
| Regurgitation | 6.0 | 38.9 | 62.3 | 35.2 | 18.0 | 79.3 % |
| Heartburn and regurgitation | 4.1 | 43.2 | 67.6 | 40.5 | 22.9 | 78.9 % |
| Irritable Bowel Syndrome | 16.7 | 20.4 | 41.7 | 13.2 | 8.4 | 81.5 % |
* excludes anyone reporting either bothersome heartburn or acid regurgitation. BDR (bronchodilator response) = 10% or greater increase in FEV1 following salbutamol.
Association of asthma diagnosis and respiratory symptoms with reflux symptoms and irritable bowel syndrome at age 26 years
| Heartburn | Regurgitation | Heartburn and regurgitation | Irritable Bowel Syndrome | ||||||
| n | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| Asthma | 903 | 1.75 (1.11, 2.76) | 0.017 | 2.76 (1.54, 4.96) | 0.001 | 3.22 (1.62, 6.40) | 0.001 | 1.10 (0.71, 1.71) | 0.67 |
| Wheeze | 897 | 1.65 (1.10, 2.46) | 0.015 | 2.84 (1.59, 5.06) | <0.001 | 3.53 (1.74, 7.18) | <0.001 | 1.25 (0.87, 1.79) | 0.23 |
| Cough | 903 | 2.02 (1.23, 3.33) | 0.005 | 3.48 (1.88, 6.45) | <0.001 | 4.27 (2.09, 8.72) | <0.001 | 0.83 (0.49, 1.40) | 0.49 |
All analyses are by logistic regression using the respiratory outcomes as the dependent variables and are adjusted for sex and body mass index. OR = odds ratio, 95% CI = 95% confidence intervals.
Associations between lung function, bronchodilator responsiveness and reflux symptoms and irritable bowel syndrome in women and men.
| Heartburn | Regurgitation | Heartburn and regurgitation | Irritable Bowel Syndrome | |||||||
| n | Coeff (95% CI) | p | Coeff (95% CI) | p | Coeff (95% CI) | P | Coeff (95% CI) | p | ||
| FEV1/FVC | Women | 402 | -0.52 (-2.72, 1.68) | 0.643 | -5.14 (-8.09, -2.20) | 0.001 | -5.55 (-9.07, -2.04) | 0.002 | 0.04 (-1.58, 1.65) | 0.966 |
| Men | 464 | 0.07 (-1.80, 1.94) | 0.942 | -0.10 (-2.80, 2.61) | 0.944 | -0.28 (-3.50, 2.95) | 0.866 | -0.70 (-2.61, 1.21) | 0.473 | |
| p-itn | 0.609 | 0.013 | 0.029 | 0.618 | ||||||
| n | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | P | OR (95% CI) | p | ||
| BDR | Women | 398 | 3.53 (1.28, 9.70) | 0.015 | 8.74 (2.99, 25.6) | <0.001 | 11.5 (3.40, 38.6) | <0.001 | 0.76 (0.25, 2.30) | 0.628 |
| Men | 455 | 1.67 (0.76, 3.68) | 0.199 | 1.11 (0.32, 3.85) | 0.864 | 1.72 (0.48, 6.13) | 0.403 | 1.59 (0.70, 3.61) | 0.270 | |
| p-itn | 0.256 | 0.014 | 0.035 | 0.300 | ||||||
The FEV1/FVC ratio is analysed by linear regression and bronchodilator response by logistic regression. Analyses use these as the dependent variables and are adjusted for BMI. Coeff = regression coefficient, OR = odds ratio, 95% CI = 95% confidence intervals, p-itn = p value for interaction between sex and reflux symptoms, BDR = 10% or greater increase in FEV1 following salbutamol.
Associations between reflux symptoms and respiratory outcomes in atopic and non-atopic Study members.
| Heartburn | Regurgitation | Heartburn and Regurgitation | |||||||
| Non-atopic | Atopic | Non-atopic | Atopic | Non-atopic | Atopic | ||||
| OR (95% CI) | OR (95% CI) | p-itn | OR (95% CI) | OR (95% CI) | p-itn | OR (95% CI) | OR (95% CI) | p-itn | |
| Asthma | 1.81 (0.64, 5.17) | 1.96 (1.12, 3.44) | 0.873 | 4.03 (1.11, 14.5) | 2.54 (1.23, 5.24) | 0.603 | 3.51 (0.80, 15.3) | 3.16 (1.35, 7.38) | 0.827 |
| Wheeze | 2.88 (1.40, 5.90) | 1.30 (0.76, 2.20) | 0.072 | 7.27 (2.23, 23.7) | 1.93 (0.95, 3.93) | 0.062 | 6.56 (1.68, 25.6) | 2.54 (1.07, 6.00) | 0.253 |
| Cough | 4.67 (1.98, 11.0) | 1.46 (0.73, 2.92) | 0.039 | 5.90 (1.94, 18.0) | 2.88 (1.30, 6.38) | 0.315 | 10.8 (3.02, 38.6) | 2.87 (1.12, 7.34) | 0.099 |
| BDR | 2.81 (0.70, 11.3) | 2.08 (0.99, 4.36) | 0.760 | 7.57 (1.76, 32.5) | 1.76 (0.64, 4.86) | 0.108 | 12.7 (2.71, 59.6) | 2.08 (0.67, 6.50) | 0.067 |
| Coeff (95% CI) | Coeff (95% CI) | Coeff (95% CI) | Coeff (95% CI) | Coeff (95% CI) | Coeff (95% CI) | ||||
| FEV1/FVC | 0.80 (-1.24, 2.84) | -1.15 (-3.13, -0.82) | 0.213 | -2.43 (-5.37, 0.51) | -2.27 (-4.95, 0.41) | 0.940 | -1.91 (-5.34, -1.51) | -2.56 (-5.79, 0.66) | 0.808 |
Non-atopic groups (n = 278) and atopic (n = 536) defined by skin-prick tests at age 21. The FEV1/FVC ratio is analysed by linear regression. All other analyses use logistic regression. Analyses use the respiratory outcomes as the dependent variables and are adjusted for BMI and sex. OR = odds ratio, Coeff = coefficient, 95% CI = 95% confidence intervals, p-itn = p value for interaction between atopic status and reflux symptoms, BDR = 10% or greater increase in FEV1 following salbutamol.
Figure 1Prevalence of reflux symptoms at age 26 according to history of asthma. No asthma = denies ever having had asthma by age 26 (n = 543). Child-persistent 9 = asthma reported at age 9 or 11 and also at age 26 (n = 70). Teen-persistent = asthma first reported at age 13, 15 or 18 and still present at age 26 (n = 42). Adult-onset = asthma first reported at age 21 or 26 (n = 78). Asthma remission = asthma reported at an earlier age, but not at 26 (n = 174). * = p < 0.05 compared to no asthma.
Figure 2Prevalence of reflux symptoms at age 26 according to history of wheeze. No wheeze = denies ever having had wheeze by age 26 (n = 249). Child-persistent = wheeze at age 9 or 11 and also at age 26 (n = 102). Teen- persistent = wheeze first reported at age 13, 15 or 18 and still present at age 26 (n = 127). Adult-onset = wheeze first reported at age 21 or 26 (n = 168). Wheeze remission = wheeze reported at an earlier age, but not at 26 (n = 174). * = p < 0.05 compared to no wheeze.
Prediction of reflux symptoms at age 26 years by history of airway hyperresponsiveness.
| Heartburn | Regurgitation | Heartburn and regurgitation | |||||||
| Challenge agent | Age | n | % with AHR | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p |
| Methacholine* | 9 | 716 | 16.9 | 1.40 (0.81, 2.43) | 0.234 | 1.22 (0.55, 2.73) | 0.623 | 1.51 (0.63, 3.61) | 0.354 |
| 11 | 677 | 10.8 | 1.62 (0.84, 3.11) | 0.150 | 1.89 (0.80, 4.48) | 0.147 | 3.00 (1.22, 7.40) | 0.017 | |
| 13 | 637 | 8.3 | 1.63 (0.76, 3.51) | 0.210 | 1.78 (0.66, 4.82) | 0.253 | 2.92 (1.04, 8.17) | 0.041 | |
| 15 | 743 | 8.3 | 1.92 (1.00, 3.70) | 0.051 | 2.94 (1.35, 6.42) | 0.007 | 3.86 (1.66, 8.97) | 0.002 | |
| 21 | 795 | 7.7 | 2.59 (1.38, 4.85) | 0.003 | 4.61 (2.26, 9.40) | <0.001 | 5.56 (2.53, 12.2) | <0.001 | |
| Salbutamol | 18 | 758 | 7.8 | 1.01 (0.46, 2.21) | 0.978 | 1.13 (0.39, 3.29) | 0.818 | 1.14 (0.34, 3.85) | 0.836 |
At age 18 years, responsiveness to salbutamol bronchodilator was measured. At ages 9, 11, 13, 15 and 21 years responsiveness to methacholine was measured unless a low FEV1 precluded methacholine challenge. Airway hyperresponsiveness (AHR) was defined as a PC20 methacholine of 8 mg/mL or less or an increase in FEV1 of 10% or bronchodilator. OR = odds ratio, 95% CI = 95% confidence intervals. Analyses are by logistic regression using reflux symptoms as the dependent variables and are adjusted for sex.